Immunogenicity and safety of double versus standard dose of the seasonal influenza vaccine in solid-organ transplant recipients: A randomized controlled trial.

Détails

ID Serval
serval:BIB_38C298B3CEB2
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Immunogenicity and safety of double versus standard dose of the seasonal influenza vaccine in solid-organ transplant recipients: A randomized controlled trial.
Périodique
Vaccine
Auteur(s)
Mombelli M., Rettby N., Perreau M., Pascual M., Pantaleo G., Manuel O.
ISSN
1873-2518 (Electronic)
ISSN-L
0264-410X
Statut éditorial
Publié
Date de publication
01/10/2018
Peer-reviewed
Oui
Volume
36
Numéro
41
Pages
6163-6169
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
The use of vaccines with higher doses of antigen is an attractive strategy to improve the immunogenicity of influenza vaccination in transplant recipients. However, the effect of vaccination with a double-dose (DD) containing 30 µg of antigen in this population remains unknown.
We performed a randomized controlled trial to compare the immunogenicity and safety of DD (30 µg) vs. standard dose (SD, 15 µg) of a trivalent inactivated influenza vaccine in kidney and liver transplant recipients. Immunogenicity was assessed by hemagglutination-inhibition assay. Vaccine response was defined as seroconversion to at least one viral strain 2 weeks after vaccination and seroprotection as a titer ≥40.
Sixty-three kidney and 16 liver transplant recipients were enrolled. Forty patients received the DD and 39 the SD vaccine. Overall, 40% of patients in the DD compared to 26% in the SD group (P = 0.174) responded to vaccine. In the DD arm, more patients were seroprotected to all viral strains after vaccination (88% vs 69%, P = 0.048). Post vaccination geometric mean titers of antibodies were 131.9 vs. 89.7 (P = 0.187) for H1N1, 185.4 vs. 138.7 (P = 0.182) for H3N2, and 96.6 vs. 68.8 (P = 0.081) for influenza B with the DD vs. SD. In both groups, most of the adverse events were mild and no vaccine-related severe adverse events were observed.
Double-dose influenza vaccine is safe and may increase antibody response in transplant recipients. In this population, DD vaccination could be an alternative when high-dose vaccine is not available. NCT02746783.
Mots-clé
Adult, Aged, Antibody Formation/physiology, Drug Administration Schedule, Female, Humans, Influenza Vaccines/administration & dosage, Influenza Vaccines/adverse effects, Influenza Vaccines/therapeutic use, Influenza, Human/prevention & control, Male, Middle Aged, Transplant Recipients/statistics & numerical data, Vaccination/adverse effects, Young Adult, Double dose, Immunogenicity, Influenza vaccine, Transplant recipients
Pubmed
Web of science
Création de la notice
10/09/2018 12:37
Dernière modification de la notice
20/08/2019 13:28
Données d'usage